Accord Healthcare Launches Denosumab Biosimilar for Bone Health

Accord Healthcare has announced the launch of Osvyrti and Jubereq, biosimilars to Amgen's Prolia and Xgeva, respectively. This marks their second entry into the bone health biosimilar market. The launch follows the European Medicines Agency's approval in September 2025, after the reference medicines' patent expiry.

These biosimilars are approved for multiple bone-related conditions, such as osteoporosis and bone loss in cancer treatment. Osvyrti is indicated for osteoporosis in postmenopausal women and men, as well as bone loss linked to hormone ablation and glucocorticoid therapy in men with prostate cancer. Jubereq targets skeletal events in adults with advanced bone-involved malignancies and giant cell tumors.

Accord's CEO Paul Tredwell emphasized the biosimilars' potential to reduce treatment costs and enhance patient access to therapies. This aligns with Accord's goal of launching 20 biosimilars by 2030, addressing the growing burden of osteoporosis globally.